Back
Revance Therapeutics Quote, Financials, Valuation and Earnings
Trump wins! Dow to 75,000? Details here
See the explosive "Document 20" details here.
Sell
15
RVNC
Revance Therapeutics
Last Price:
4.30
Seasonality Move:
7.02%
7 Day Trial
ALL ACCESS PASS
$
7
U.S. Government Report Alert Tuesday
Discover the Secret LoopholeRevance Therapeutics Price Quote
$4.30
+0.05 (+1.18%)
(Updated: November 14, 2024 at 11:20 AM ET)
Revance Therapeutics Key Stats
Sell
15
Revance Therapeutics (RVNC)
is a Sell
Day range:
$4.00 - $4.29
52-week range:
$2.30 - $9.75
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1.55
P/B ratio:
0%
Volume:
2M
Avg. volume:
2.3M
1-year change:
-26.85%
Market cap:
$433.2M
Revenue:
$234M
EPS:
$-1.94
How Much Does Revance Therapeutics Make?
-
How Much Are Revance Therapeutics's Sales Annually?
RVNC Revenues are $234M -
How Much Profit Does Revance Therapeutics's Make A Year?
RVNC net income is -$324M
Is Revance Therapeutics Growing As A Company?
-
What Is Revance Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.11% -
What Is Revance Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Revance Therapeutics Stock Price Performance
-
Did Revance Therapeutics Stock Go Up Last Month?
Revance Therapeutics share price went down by -19.51% last month -
Did RVNC's Share Price Rise Over The Last Year?
RVNC share price fell by -26.85% over the past 1 year
What Is Revance Therapeutics 52-Week High & Low?
-
What Is Revance Therapeutics’s 52-Week High Share Price?
Revance Therapeutics has traded as high as $9.75 over the past 52 weeks -
What Is Revance Therapeutics’s 52-Week Low Share Price?
Revance Therapeutics has traded as low as $2.30 over the past 52 weeks
Revance Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Revance Therapeutics?
-
How Much Debt Does Revance Therapeutics Have?
Total long term debt quarterly is $431.2M -
How Much Cash Does Revance Therapeutics Have?
Cash and short term investments quarterly total is $184.1M -
What Is Revance Therapeutics’s Book Value Per Share?
Book value per share is -1.55
Is Revance Therapeutics Cash Flow Positive?
-
What Is RVNC Cash Flow From Operations?
Cash flow from operations (TTM) is -$190.9M -
What Is Revance Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $81.7M -
What Is Revance Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$12.9M
Revance Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
RVNC return on invested capital is -61.49% -
What Is Revance Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -37.25% -
What Is RVNC Return On Equity?
ROE is a measure of profitability and is 0%
Revance Therapeutics Earnings Date & Stock Price
-
What Is Revance Therapeutics's Stock Price Today?
A single share of RVNC can be purchased today for 4.25 -
What Is Revance Therapeutics’s Stock Symbol?
Revance Therapeutics trades on the nasdaq under the ticker symbol: RVNC -
When Is Revance Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Revance Therapeutics is scheduled on February 28, 2025 -
When Is RVNC's next ex-dividend date?
Revance Therapeutics's next ex-dividend date is May 15, 2020 -
How To Buy Revance Therapeutics Stock?
You can buy Revance Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Revance Therapeutics Competitors
-
Who Are Revance Therapeutics's Competitors?
Below is a list of companies who compete with Revance Therapeutics or are related in some way:
Revance Therapeutics Dividend Yield
-
What Is RVNC Dividend Yield?
Revance Therapeutics’s dividend yield currently is 0% -
What Is Revance Therapeutics’s Payout Ratio?
Revance Therapeutics’s payout ratio is 0% -
When Did Revance Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 14, 2024 -
What Is Revance Therapeutics’s Dividend Per Share?
Revance Therapeutics pays a dividend of $0.00 per share
Revance Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 6.33% |
| Revenue: | 10.66% | -12.17% |
Analyst Recommendations
| Buy Recommendations: | 1 |
|---|---|
| Hold Recommendations: | 8 |
| Sell Recommendations: | 0 |
| Price Target: | 9.23 |
| Upside from Last Price: | 117.08% |